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Abstract
Background: Membrane complement regulatory proteins (mCRPs) inhibit complement-mediated
killing of human cells by human complement, a property that confers protection from complement
to malignant breast cancer cells and that thwarts some immunotherapies. Metabolic mechanisms
may come into play in protecting cancer cells from the complement system subsequent to relatively
low levels of complement deposition.
Results: In differentiating these mechanisms, two types of human breast cancer cell lines, MCF7
(adenocarcinoma) and Bcap37 (medullary carcinoma) were cell-cycle synchronized using
glutamine-deprivation followed by restoration. These cells were examined for the expression of
two mCRPs (CD59 and CD55), and for subsequent susceptibility to antibody-mediated
complement-induced membrane damage. After glutamine restoration, MCF7 and Bcap37 cells
were synchronized into the G2/M phase and an average increased expression of CD59 and CD55
occurred with a corresponding resistance to complement-mediated damage. Blocking CD59
inhibitory function with monoclonal antibody revealed that CD59 played a key role in protecting
unsynchronized Bcap37 and MCF7 cancer cells from the complement membrane attack complex.
Interestingly, glutamine-deprivation did not significantly affect the expression of proteins e.g., the
surface level of CD59 or CD55, but did increase the susceptibility to complement-mediated killing.
One possible explanation is that glutamine-deprivation may have slowed the turnover rate of
mCRPs, preventing the cells from replacing pre-existing mCRPs, as they became neutralized by
covalent C4b and C3b depositions.
Conclusion:  Taken together the findings are consistent with the conclusion that future
immunotherapies should aim to achieve a highly specific and profound activation and deposition of
complement as well as to disrupt the synthesis and expression of CD59 and CD55 by the cancer
cells.
Background
The complement system is a critical arm of the immune
system that allows the system to eliminate pathogens.
Complement is classically activated by the presence of
antibodies on cell surface antigens. If allowed to proceed
uninhibited, a complement activation cascade occurs that
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culminates in elimination of an antibody-coated cell via
phagocytosis or lysis. Complement control mechanisms
maximize the efficiency of the complement system in spe-
cifically targeting sensitized pathogens, while sparing inci-
dental damage to nearby host cells. Indeed, membrane-
associated complement regulatory proteins (mCRPs) are
often over-expressed on host cells in areas of inflamma-
tion and restrict complement-mediated membrane dam-
age after the inadvertent deposition of the complement
components C4b or C3b [1]. In addition, malignant can-
cer cells express mCRPs [2,3] and may release soluble
forms of selected mCRPs [4] which protect them against
complement-mediated cell killing.
Fluid phase complement regulators, such as C1-inhibitor
prevent the unnecessary consumption and depletion of
soluble complement components, so as to allow a more
effective and specifically directed complement-mediated
attack on sensitized pathogens. However in the absence of
sufficient levels of antibody deposition, this and other
complement control mechanisms tend to restrict the abil-
ity of complement to eliminate cancer cells [2,5-9]. Cur-
rent therapeutic mAbs as well as endogenous low affinity
IgG antibodies to cancer cells often recruit the comple-
ment component C1qr2s2  with such low avidity that
serum C1-inhibitor is able to rapidly inhibit activated C1r
and C1s, and in most cases quickly remove the entire
C1qr2s2 complex from the antibody-coated cell surface,
resulting in only a trace level of C4b-deposition [10-12].
Meanwhile, CD55 and CD46 on malignant cells restrict
deposited C4b and C3b, and CD59 inhibits complement
membrane attack complex formation, therein protecting
cancer cells from membrane damage [13,14]. When the
complement cascade is strongly activated, the comple-
ment components C4b and C3b bind to mCRPs and inac-
tivate them, but low levels of complement depositions are
incapable of neutralizing sufficient percentages of the
expressed mCRPs on the surface of the cancer cells.
Indeed, repeated low level, albeit ineffective, comple-
ment-depositions are capable of inducing metabolic con-
sequences that may result in an undesirable increase in
resistance to apoptotic influences [15,16] and could
enhance resistance to complement-mediated killing
[17,18], therein providing an acquired advantage for the
surviving cancer cell populations [19]. Therefore, when
designing antibody therapies to utilize complement in the
elimination of malignant cancer cells, highly effective
classical pathway activation may be needed to mediate
sufficient C4b and C3b depositions to covalently bind
and block the function of mCRPs on the targeted cancer
cell surface.
Cell cycle dependent phenomena and resultant expres-
sion of targeted antigens have been associated with vari-
ant susceptibilities to complement-mediated lysis [20-
22]. However, many of these studies were conducted just
as CD59 and CD55 were being fully characterized and
several studies used cross-species complement. In addi-
tion, few reports have examined the effect of cell-cycle
synchronization on the expression of mCRPs in breast
cancer cell lines. In this study, the expression levels of
CD59 and CD55 were measured in two different types of
human breast cancer cell lines, a human breast adenocar-
cinoma cell line MCF7 [23] and a human breast medul-
lary carcinoma cell line Bcap37 [24] before and after cell
cycle synchronization using glutamine-deprivation and
restoration. The expression levels of CD59 and CD55
were correlated to susceptibility to human complement-
mediated lysis following complement activation. Com-
plement was activated by exposing cancer cells to excess
levels of polyclonal rabbit antibodies to β2-microglobu-
lin, a stably and abundantly expressed antigen on cancer
cell line surfaces [23,25]. Use of this polyclonal antibody
to activate C1 blocks the rapid entrance and action of C1-
inhibitor [10,11] allowing sufficient progression of the
complement cascade so as to allow a relative measure-
ment of the impact of mCRPs on complement-mediated
cell damage.
In these studies we found that glutamine deprivation
increases breast cancer cell susceptibility to complement-
mediated killing. We also found that subsequent
glutamine restoration produces cancer cells that substan-
tially up-regulate the expression of the mCRPs CD59 and
CD55 on the cell surface and that these glutamine-
restored cancer cells are even more resistant to comple-
ment-mediated damage than unsynchronized breast can-
cer cells.
Results
Complement-mediated lysis of antibody-coated breast 
cancer cells as a function of the level of normal human 
serum as a source of complement
Normal human serum (NHS) is a readily available and
reliable source that contains the entire battery of comple-
ment proteins needed to evoke the immunological cas-
cade of antibody-directed complement-mediated cell
lysis. As lytic damage to the cell membrane occurs, intrac-
ellular enzymes and elements are released into the extra-
cellular domain, allowing them to become markers in
determining the extent of cellular damage incurred during
complement-mediated lysis. In this manner, a commer-
cially available Lactate Dehydrogenase (LDH) assay
(Sigma Diagnostics) was employed to detect the extent of
total complement-mediated cell lysis.
In NHS, however, various levels of background LDH activ-
ity can be detected. Serial dilutions of NHS were devel-
oped to identify the most appropriate concentration of
NHS that could be used in further experimentation dem-Cell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
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onstrating minimal background LDH activity, while opti-
mizing detection of LDH activity as an index of antibody-
directed complement-mediated lysis. II BothThe use of
25% NHS as a source of complement provided the maxi-
mal level of complement-mediated lysis [26], while
allowing an acceptable serum-LDH background. Detec-
tion of complement-mediated membrane damage to anti-
β2-microglobulin sensitized cancer cells, monitored via
release of LDH (and Trypan Blue exclusion), indicated
that 20% of the MCF7 cells and 18% of the Bcap37 cells
were lysed (Figure 1). As NHS was further diluted, both
MCF7 and Bcap37 cells became increasingly resistant to
complement-mediated membrane damage. Therefore
25% NHS as a source of complement was used through-
out the remaining studies.
Neutralization of CD59 enhanced complement-mediated 
lysis of breast cancer cells
The cell surface marker CD59 (Protectin) prevents forma-
tion of the membrane attack complex, the terminal arm of
the activated complement system responsible for induc-
ing cell lysis. Thus, CD59 is considered one of the most
important innate defense mechanisms cells have against
complement activation. The YTH53.1 monoclonal anti-
body (Serotec, Raleigh, NC) has been proven to bind to
CD59 on the surface of human cells and neutralize the
complement inhibitory function of CD59 (37,38). Our
objective was to determine the specific degree of protec-
tion CD59 offers MCF7 and Bcap37 breast cancer cells
from antibody-directed complement-mediated damage.
The MCF7 and Bcap37 cells received the combined treat-
ment of YTH53.1 along with anti-β2-microglobulin anti-
bodies followed by 25% NHS. Cells treated with only the
YTH53.1 anti-CD59 monoclonal antibody demonstrated
only 7% lysis for Bcap37 and 11% lysis for MCF7 cells
(Figure 2, Treatment group 3). The relatively small levels
of lysis attributed to YTH53.1 alone were due to inhibi-
tion of CD59 function and mild complement activation
and regarded as background lysis. When treated with only
20 µg of rabbit polyclonal anti-β2-microglobulin antibod-
ies, the percent lysis for Bcap37 cells was 33% and for
MCF7 cells was 42%. However, when 20 µg of YTH53.1
anti-CD59 monoclonal antibodies were combined with
the anti-β2-microglobulin antibodies, the percent lysis sig-
nificantly increased to 52% for Bcap37 cells (Figure 2,
Treatment groups B and F: p value = 0.009) and 59% for
MCF7 cells (Figure 2, Treatment groups B and F: p value =
0.005). Thus, neutralization of CD59 function with
YTH53.1 significantly increased complement-mediated
lysis of breast cancer cells.
No significant difference was observed between Bcap37
and MCF7 cells treated with 20 µg of YTH53.1 and either
10 or 20 µg of rabbit polyclonal anti-β2-microglobulin
Neutralization of CD59 enhanced complement-mediated  lysis Figure 2
Neutralization of CD59 enhanced complement-mediated 
lysis. In A through D, Bcap37 and MCF7 cells (1 × 105) were 
sensitized with 20 µg of rabbit antibody to β2-microglobulin 
(anti-β2M) with or without specified doses of mAb-YTH53.1 
(anti-CD59). Background LDH activity was obtained with 
unsensitized cells similarly incubated with 25% NHS for 4.5 
hours to provide a numerical value that was subtracted from 
experimental values. Experimental antibody combinations are 
represented as follows: 1) 10 µg anti-β2M alone (28.0% lysis 
± 1.7). 2) 20 µg anti-β2M alone (42.3% lysis ± 2.9). 3) 20 µg 
mAb-YTH53.1 alone (11.3% lysis ± 1.5). 4) 20 µg anti-β2M + 
5 µg mAb-YTH53.1 (43.3% lysis ± 2.1). 5) 20 µg anti-β2M + 
10 µg mAb-YTH53.1 (53% lysis ± 4.8). 6) 20 µg anti-β2M + 
20 µg mAb-YTH53.1 (59% lysis ± 4.9).
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Optimal NHS Dilution for Complement-mediated lysis of  human breast cancer cell lines Figure 1
Optimal NHS Dilution for Complement-mediated lysis of 
human breast cancer cell lines. The Bcap37 and MCF7 cells (1 
× 105) were sensitized 20 µg rabbit antibody to β2-
microglobulin and incubated with specified dilutions of nor-
mal human serum (NHS). After a total 4.5 hours of incuba-
tion at 37°C, supernatants were collected and tested for 
LDH activity to determine percent lysis.Cell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
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antibodies. However, Bcap37 cells treated with anti-β2-
microglobulin antibodies and 5 µg of YTH53.1 demon-
strated 34% lysis, while cells treated with anti-β2-
microglobulin antibodies and 20 µg of YTH53.1 demon-
strated 52% lysis (Figure 2, Treatment groups D and F; p
value = 0.05). Likewise, MCF7 cells treated with anti-β2-
microglobulin antibodies and 5 µg of YTH53.1 demon-
strated 43% lysis, while cells treated with anti-β2-
microglobulin antibodies and 20 µg of YTH53.1 demon-
strated 59% lysis (Figure 2, Treatment groups D and F; p
value = 0.02). With the YTH53.1 antibody demonstrating
a dose-response, the 20 µg of YTH53.1 was selected as an
effective amount in eliciting complement-mediated lysis
for further experimentation.
Cell cycle synchronization with glutamine deprivation and 
restoration
Using flow cytometry, cells in different phases of the cell
cycle are identified based on the amount of DNA present
inside the cell, since duplication of genetic material occurs
during progression of the cell cycle when a diploid cell
prepares for mitotic division. Specifically, propidium
iodide intercalates within DNA providing a fluorescent
marker that allows measurement of total DNA material by
flow cytometry. Diploid cells in the G0-G1 phase are
denoted as having a total DNA content of 2C, while cells
in S phase have a total DNA content between 2C and 4C,
and cells in G2-M phase have a total DNA content of 4C.
Discrimination between G0 and G1 phases is not possible
because the amount of DNA is identical (2C) for cells in
either the G0 or G1 phase, thus cells with 2C DNA were
grouped together as G0-G1 phase. Similarly, the amount
of DNA is identical for cells in either the G2 or M phase,
thus cells with 4C DNA were grouped together as G2-M
phase.
Glutamine is an amino acid routinely added to cell culture
media due to its importance in the regulation of cell
metabolism through its association with the synthesis of
both protein and DNA (27). Glutamine-deprivation has
been used as a method of arresting cells in the G0 phase
of the cell cycle (39). When glutamine is restored to the
culture media, the cells are able to then proceed unim-
peded through the cell cycle. After Bcap37 and MCF7 cells
had been deprived of glutamine for 48 hours, 2 mM L-
glutamine was added to the culture medium. Distinct cell
cycle profiles were characterized for Bcap37 and MCF7
cells subjected to glutamine synchronization when com-
pared with unsynchronized cells. Distribution of popula-
tion averages were calculated for G0-G1 phase, S phase,
and G2-M phase among unsynchronized and synchro-
nized cells. Unsynchronized Bcap37 cells demonstrated
61% in G0-G1 phase, 22% in S phase and 16% in G2-M
phase (figure 3a). Glutamine deprived Bcap37 cells dem-
onstrated 61% in G0-G1 phase, 32% in S phase and 4%
in G2-M phase. Glutamine restored Bcap37 cells demon-
strated 25% in G0-G1 phase, 34% in S phase and 41% in
G2-M phase. Unsynchronized MCF7 cells demonstrated
60% in G0-G1 phase, 24% in S phase and 17% in G2-M
phase (figure 3a). Glutamine deprived MCF7 cells dem-
onstrated 68% in G0-G1 phase, 24% in S phase and 4%
in G2-M phase. Glutamine restored MCF7 cells demon-
strated 27% in G0-G1 phase, 35% in S phase and 38% in
G2-M phase. Thus, the cell cycle profile changes signifi-
cantly depending on the presence or absence of glutamine
revealing that glutamine depletion synchronizes cells by
arresting progression predominantly in G0-G1 phase.
However, upon restoration of glutamine the cell cycle pro-
file is further altered with an abrupt forward progression
into G2-M phase. Therefore, glutamine depletion and res-
toration affords the unique ability to synchronize the cell
cycle, resulting in significant shifts in the proportion of
MCF7 and Bcap37 cells in G0-G1 phase, S phase or G2-M
phase. Further, cells receiving glutamine following
glutamine deprivation demonstrated a common shift in
the proportion of cells in the quiescent G0-G1 phase to
active mitotic proliferation of G2-M phase, the most char-
acteristic stage of neoplastic transformation.
The effect of glutamine deprivation and restoration on the 
expression of CD59 and CD55
With glutamine synchronization resulting in significant
shifts in the cell cycle profiles for Bcap37 and MCF7 cells,
the cells were then examined to determine if glutamine
synchronization impacted CD59 and CD55 expression.
Bcap37 and MCF7 cells were synchronized with
glutamine deprivation for 48 hours, then subsequently
received 2 mM L-glutamine for 8 hours. Following
glutamine restoration, cells were harvested and prepared
analysis by flow cytometry. Using the ModFit LT software,
the Mean Fluorescence Intensity (MFI) was examined
with the cell acquisition being approximately 5,000 cells
for each treatment group (data not shown). The MFI was
examined for CD59, CD55 and the appropriate negative
isotype controls for unsynchronized and glutamine
restored cells. The negative background isotype controls
(non-specific FITC-labeled mouse immunoglobulins, IgG2a
and IgG) revealed negligible cell surface binding. Com-
pared with unsynchronized cells, glutamine restoration
resulted in a 3.5-fold increase in and a 3.1-fold increase in
CD55 expression for Bcap37 cells (Figure 4a). Similar
results were observed for MCF7 cells upon glutamine-res-
torationwith a 3.7-fold increase in CD59 expression and a
2.2-fold increase in CD55 expression (Figure 4b). Thus,
glutamine restoration resulted in increased CD59 and
CD55 expression for Bcap37 and MCF7 cells when con-
trolled for cell number. Therefore, glutamine restoration
not only induced Bcap37 and MCF7 cells to rapidly
progress through the cell cycle, but also augmented theCell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
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levels of CD59 and CD55 expression along with the
mitotic index.
Comparison of CD59 and CD55 expression in G0-G1 and 
G2-M phases of the cell cycle
Given the distinct cell cycle profiles observed with
glutamine-deprived and glutamine-restored cells, the pos-
sibility existed that the increase in CD59 and CD55
expression might be directly related to the cell cycle phase.
To determine if CD59 or CD55 expression was phase spe-
cific, flow cytometry was used to isolate the G0-G1 and
the G2-M subpopulations of Bcap37 and MCF7 cells
within each synchronization group. During Cell Analysis
using the FACSCalibur device and ModFit LT software, the
distinct populations of cells were identified in either G0-
G1 or G2-M based on channel values dictated by the
amount of propidium iodide intercalated within DNA. All
diploid cells (2C) were identified, then separated accord-
ing to channel values based on propidium iodide fluores-
cence at 585 nm (data not shown). Cells identified as G0-
G1 had channel values ranging approximately from 25 to
75. Cells identified as G2-M had channel values ranging
approximately from 140 to 175. Gating was performed
manually after identification of G0-1 and G2-M popula-
tions to further determine CD59 and CD55 MFI among
these distinct populations of cells at different stages in the
cell cycle. Using the ModFit LT software, the Mean Fluo-
rescence Intensity (MFI) was examined with the cell acqui-
sition being approximately 5,000 cells for each treatment
group (data not shown). The MFI was examined for
CD59, CD55 and the appropriate negative isotype con-
trols in the G0-G1 and G2-M channel ranges for unsyn-
chronized and glutamine restored cells. The negative
background isotype controls (non-specific FITC-labeled
mouse immunoglobulins, IgG2a and IgG) revealed negligible
cell surface binding. Since glutamine-deprived Bcap37
and MCF7 cells had only 4% of total cells in G2-M, an
inadequate number of cells were available for determina-
Cell cycle distribution for breast cancer cells subjected to glutamine-mediated synchronization Figure 3
Cell cycle distribution for breast cancer cells subjected to glutamine-mediated synchronization. Data are depicted as represent-
ative means for three independent experiments. Bcap37 cells (Figure 3a) and MCF7 cells (Figure 3b) were grown to confluency 
and either maintained in media with glutamine (Unsynchronized) or without glutamine for 48 hours (Gln Deprived), or without 
glutamine for 48 hours but then followed by 8 hours with glutamine (Gln Restored). All cells were harvested and treated with 
0.5 mg/ml propidium iodide to determine cell cycle distribution by FACS analyses.
A
BCell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
Page 6 of 13
(page number not for citation purposes)
tion of MFI for CD59 and CD55. However, the G2-M sub-
populations for the unsynchronized and glutamine
restored Bcap37 and MCF7 cells contained a sufficient
number of cells for analysis. When comparing the MFI for
CD59 and CD55 between G0-G1 and G2-M subpopula-
tions of cells in different phases of the cell cycle, no signif-
icant difference in mCRP expression was observed for
Bcap37 or MCF7 cells (Figures 5a and 5b). Therefore, the
increased expression of CD59 and CD55 observed with
glutamine restoration appears to not be directly related to
the increased proportion of cells in the G2-M phase of the
cell cycle. Rather, other factors that are not cell cycle-
dependent, yet associated with the metabolic prolifera-
tion stimulated by glutamine restoration are responsible
for the increased expression of mCRPs.
Influence of glutamine deprivation or restoration on 
complement susceptibility
With the presence or absence of glutamine impacting the
expression levels of mCRPs, the susceptibility of breast
cancer cells to complement-mediated lysis also is likely
dependent on the relative level of glutamine in the cellu-
lar microenvironment. To determine if changes in expres-
sion levels of CD59 and CD55 altered their susceptibility
to complement-mediated lysis, unsynchronized,
glutamine-deprived and glutamine-restored cells were
treated with complement-activating antibodies and incu-
bated with NHS for 4 hours to determine the percentage
of complement-mediated lysis. When treated with 20 µg
of rabbit polyclonal anti-β2-microglobulin antibodies,
unsynchronized Bcap37 cells demonstrated 26% lysis
(Figure 6). However, when Bcap37 cells were cultured in
a glutamine-deficient medium, complement-mediated
damage significantly increased to 37% (p value = 0.007).
Further, when glutamine was restored to the media fol-
lowing a 48-hour period of deprivation, Bcap37 cells
demonstrated 17% lysis, a significant reduction in com-
plement susceptibility compared to either unsynchro-
nized or glutamine deprived cells (p values = 0.05 and
0.003, respectively). The impact of glutamine synchroni-
zation affected the MCF7 cells similarly. When treated
with 20 µg of rabbit polyclonal anti-β2-microglobulin
antibodies, unsynchronized MCF7 cells demonstrated
37% lysis. Yet, MCF7 cells cultured in glutamine-deficient
media demonstrated a significant increase in complement
susceptibility with 54% lysis (p value = 0.01). Addition-
ally, when glutamine is restored to the media, MCF7 cells
demonstrated a significant decrease in complement sus-
ceptibility compared with glutamine-deprived cells illus-
trated by 26% lysis (p value = 0.007).
As expected, glutamine restored Bcap37 and MCF7 cells
with increased CD59 and CD55 expression exhibited
heightened resistance to complement-mediated lysis.
Interestingly, when compared with unsynchronized cells,
glutamine deprived Bcap37 and MCF7 cells demonstrated
increased susceptibility to complement-mediated lysis
although expression levels of CD59 and CD55 were simi-
lar (figures 4a and 4b). Thus, the increased expression of
CD59 and CD55 enhance complement resistance, how-
ever, other factors associated with glutamine deprivation
beyond expression levels of mCRPs also influence com-
plement susceptibility.
Neutralization of CD59 augments complement-mediated 
lysis following glutamine synchronization
Glutamine synchronization altered the expression levels
of mCRPs, cell cycle profiles, and complement suscepti-
bility among breast cancer cells, suggesting microenviron-
mental perturbations likely influence complement-
activating antibody-directed breast cancer therapies.
One of the most effective mCRPs is CD59, which func-
tions to prevent formation of the membrane attack com-
plex specifically blocking the terminal arm of the
complement cascade. The YTH53.1 monoclonal antibody
(Serotec, Raleigh, NC) has been proven to bind to CD59
Expression of CD59 and CD55 in breast cancer cells sub- jected to glutamine-mediated synchronization Figure 4
Expression of CD59 and CD55 in breast cancer cells sub-
jected to glutamine-mediated synchronization. Data is 
depicted as representative means for three independent 
experiments. Bcap37 cells (Figure 4a) and MCF7 cells (Figure 
4b) were grown to confluency and either maintained with 
glutamine (Unsynchronized) or in the same media without 
glutamine for 48 hours (Glutamine Deprived), or in the same 
media without glutamine for 48 hours followed by 8 hours 
with glutamine (Glutamine Restored). In all experimental 
groups for Bcap37 and MCF7 cells, CD59 was quantified 
using FITC-conjugated anti-CD59 mouse monoclonal anti-
body and CD55 was quantified using FITC-conjugated anti-
CD55 mouse monoclonal antibody.
A
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on the surface of human cells and neutralize its comple-
ment inhibitory function (37,38). Our objective was to
determine the specific degree of protection CD59 offers
Bcap37 and MCF7 breast cancer cells from antibody-
directed complement-mediated damage when simultane-
ously challenged with glutamine synchronization.
For Bcap37 and MCF7 cells, the YTH53.1 monoclonal
antibody was used in combination with complement acti-
vating anti-β2-microglobulin antibodies and 25% NHS.
Unsynchronized Bcap37 cells demonstrated 42% lysis
(Figure 7). Following glutamine deprivation, Bcap37 cells
revealed a significant increase in complement-mediated
lysis of 61% (p value = 0.05). Additionally, glutamine res-
toration resulted in 31% lysis, revealing decreased com-
plement susceptibility when compared with the
unsynchronized and glutamine-deprived treatment
groups (p values = 0.02 and 0.01, respectively). (All of
these lysis values for Bcap37 cells are higher than those of
cells treated with only anti-β2-microglobulin as seen in
Figure 6, where unsynchronized Bcap37 cells demon-
strated 26% lysis, glutamine deprived Bcap37 cells dem-
onstrated 37% lysis, and glutamine restored Bcap37 cells
demonstrated 17% lysis). Similar observations were seen
with MCF7 cells, with unsynchronized cells demonstrat-
ing 55% lysis. Following glutamine deprivation, MCF7
cells showed a significant increase in complement-medi-
ated lysis of 72% (p value = 0.001). Further, glutamine
restoration resulted in decreased complement susceptibil-
ity with 46% lysis, a significant decrease compared with
unsynchronized and glutamine-deprived MCF7 cells (p
value = 0.02 and 0.01, respectively). (All of these lysis val-
ues for MCF7 cells are higher than those of cells treated
with only anti-β2-microglobulin as seen in Figure 6, where
unsynchronized MCF7 cells demonstrated 37% lysis,
glutamine deprived MCF7 cells demonstrated 54% lysis,
and glutamine restored MCF7 cells demonstrated 26%
lysis).
CD59 and CD55 expression in G0-G1 and G2-M subpopulations Figure 5
CD59 and CD55 expression in G0-G1 and G2-M subpopulations. Data is depicted as representative means for three independ-
ent experiments. Unsynchronized Bcap37 cells (Figure 5a) and MCF7 cells (Figure 5b) were grown to confluency and main-
tained in media supplemented with 2 mM L-glutamine (Unsynch). Synchronized cells were grown to confluency in normal 
media and then maintained in media without glutamine for 48 hours, followed by 8 hours in media supplemented with 2 mM L-
glutamine (Gln Restored). Cells were then harvested, treated with propidium iodide, incubated with either FITC-conjugated 
antibodies to CD59 or to CD55 and prepared for flow cytometric sorting and analysis.
A
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In view of these results, CD59 offers significant resistance
to complement-mediated lysis regardless of whether cells
are subjected to glutamine synchronization or not. How-
ever, when Bcap37 and MCF7 cells are faced with potent
complement activation in the face of glutamine depriva-
tion and CD59 neutralization, complement susceptibility
is markedly increased. Conversely, restoration of
glutamine seemingly reverses the increased complement
susceptibility observed with glutamine deprivation. How-
ever, neutralization of CD59 combined with potent com-
plement activation still elicited appreciable complement-
mediated lysis when compared to glutamine-restored cells
not treated with YTH53.1 (Figure 6). Additionally,
glutamine-restored Bcap37 and MCF7 cells exhibited
increased complement resistance than their unsynchro-
nized counterparts, even when CD59 was neutralized for
both treatment groups. Therefore, glutamine restoration
not only increases complement resistance by elevating
CD59 expression, but also likely induced other yet uni-
dentified intracellular responses that provided additional
resistance to complement-mediated lysis.
Discussion
Membrane complement regulatory proteins (mCRPs) that
are expressed on breast cancer cells, as well as normal cells
provide exquisite protection from complement-mediated
lysis [13,28-30], after inadvertent C4b or C3b deposition
or after a marginal initiation of the classical pathway sub-
sequent to sensitization of cancer cells by exogenous
monoclonal antibodies or low affinity endogenous anti-
bodies. Should the complement cascade override the
effects of CD55 (and CD46, another mCRP) and manage
to activate the terminal complement components on can-
cer cell membranes, functional CD59 molecules bind to
human C8 and C9, during the attempt to properly assem-
ble the membrane attack complex [31]. By preventing
complement-mediated membrane damage, CD59 con-
veys an immunological privilege to both normal host and
neoplastic cells [1,5,6,32]. The soluble complement
inhibitor, C1-inhibitor, acts at the sensitized surface to
remove C1 and block the classical pathway, but a highly
effective initiation of the classical complement pathway
by abundant levels of complement-activating polyclonal
antibodies to numerous proximate antigenic determi-
nants on cancer cell surfaces may override C1-inhibitor
[10-12], and, as shown here, may generate a profound fix-
ation of complement that results in a significant percent-
age of cell killing as measured by the release of LDH and
uptake of Trypan Blue.
In these experiments, serum is the source of complement,
but the serum also contains C1-inhibitor. The dilution of
serum from 50% to 25% caused an increased comple-
ment-mediated lysis of the sensitized cancer cells (Figure
1). We have reported previously that C1-inhibitor func-
tion is the rate-limiting step in the initiation of the classi-
cal pathway [10,11]. Therefore we suggest that under the
conditions of our experiment, the level of functional C1-
inhibitor was reduced to a defined point that allowed an
increase in C1 deposition, yet did not significantly com-
promise C1-inhibitor's ability to control fluid-phase C1
activation, which would otherwise result in depletion of
soluble complement components.
It may seem unlikely that cells expressing significant levels
of mCRPs should suffer any complement-mediated lysis.
A reasonable speculation is that the direct covalent depo-
sition of complement components (e.g., C4b and C3b)
onto a percentage of the mCRPs can inhibit the functions
of those mCRPs, therein creating pivotal conditions that
enable complement-mediated membrane damage. High
dilutions of serum also dilute complement components
(and complement control proteins) resulting in a progres-
sively lower level of complement deposition, which could
be more easily controlled by the functional mCRPs on the
cancer cell surface. For these reasons we chose to apply
excess levels of rabbit polyclonal antibodies to β2-
The effect of glutamine-mediated synchronization on com- plement susceptibility in breast cancer cell lines Figure 6
The effect of glutamine-mediated synchronization on com-
plement susceptibility in breast cancer cell lines. All popula-
tions of cells were grown to confluency in separate culture 
flasks. Unsynchronized cells were maintained in 10% FBS 
DMEM supplemented with 2 mM L-glutamine, while some 
cells were subsequently maintained in glutamine deficient-
media for 48 hours (Gln Deprived), and of this group, some 
were subsequently supplemented with 2 mM L-glutamine for 
8 hours (Gln Restored). All populations of cells were sensi-
tized with 20 µg of rabbit polyclonal antibody to β2-
microglobulin and subjected to 25% fresh normal human 
serum (NHS). After 4.5 hours of incubation with NHS at 
37°C, supernatants were collected and tested for LDH activ-
ity to determine percent lysis.Cell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
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microglobulin, a stable and ubiquitously expressed cell
surface marker. We used 25% fresh human serum in our
study of the complement-mediated killing of two differ-
ent types of breast cancer cell lines, a breast adenocarci-
noma cell line MCF7 [23], and a human breast medullary
carcinoma cell line, Bcap37. These conditions allowed an
assessment of the impact of glutamine-deprivation on cell
cycle kinetics, mCRP expression and complement suscep-
tibility in a breast cancer model.
Breast cancer cell lines subjected to a 48-hour period of
glutamine-deprivation were unable to progress through
mitosis, with the majority of cells trapped in G0-G1
phase. Trypan Blue exclusion verified the viability of all
cells at harvesting following control and experimental
treatments, including glutamine-deprivation. Restoration
of glutamine to glutamine-deprived cells induced a sub-
stantial surge in cell cycle progression, with an increased
proportion of cells in the G2-M phase. However, our anal-
ysis reveals that the expression of CD59 and CD55 is not
dependent upon phase of the cell cycle, with G0-G1 phase
cells demonstrating no significant difference in mCRP
expression compared with G2-M phase cells. Yet, the res-
toration of glutamine to glutamine-deprived cells stimu-
lated increased mCRP expression suggesting that CD59
and CD55 expression may be related more closely to met-
abolic proliferation rather than dependent on specific
phases of the cell cycle. Coincidently, the rapidly prolifer-
ating glutamine-restored breast cancer cells demonstrated
increased complement resistance in association with the
increased expression of CD59 and CD55. When account-
ing for overall cell number, the relative surface expression
level of CD59 and CD55 was observed to increase appre-
ciably in glutamine-restored breast cancer cells, which
explains the associated increased complement resistance.
However, other unidentified factors that impact comple-
ment susceptibility, such as membrane permeability and
cytoskeleton integrity, could have also been influenced by
glutamine restoration. Nonetheless, increased CD59 and
CD55 expression protect breast cancer cells form anti-
body-directed complement activation. Particularly, the
importance of CD59 was underscored in our experiments.
With CD59 neutralized, unsynchronized Bcap37 and
MCF7 cells demonstrated 42% and 55% complement
lysis, respectively. However, with functional CD59 activity
unsynchronized Bcap37 and MCF7 cells demonstrated
26% and 37% complement lysis, respectively, indicating
CD59 contributes significantly to complement resistance
in unsynchronized breast cancer cells. Other studies have
suggested CD59 is one of the major factors in providing
host cells protection from complement activation (29, 37,
38).
Interestingly, neutralization of CD59 in breast cancer cells
deprived of glutamine resulted in maximal complement-
mediated damage, with lysis of 61% of Bcap37 and 72%
of MCF7 cells. The heightened complement susceptibility
associated with glutamine deprivation was more than
completely reversed with glutamine restoration, even if
CD59 was neutralized or not. This suggests factors other
than mCRPs are recruited that provide additional comple-
ment resistance to cells entering hypermetabolic states,
similar to the phenomenon observed with glutamine res-
toration. Similar to our results, other studies have related
metabolic deficiencies with increased complement sus-
ceptibility due to structurally compromised cell mem-
branes [22,33,34], which could be more easily disrupted
by antibody-directed complement activation. Further
studies will be needed to examine and compare each of
these possibilities under the metabolic conditions
induced by glutamine-deprivation.
Chemotherapeutic agents preferentially target rapidly
proliferating cancer cells with the intention of inducing a
tumoricidal response while minimizing collateral host
damage. Many chemotherapeutic agents alter the meta-
bolic state and cytokinetic profile in a manner not unlike
glutamine-deprivation [20,21,36]. In future studies, the
specific impact chemotherapeutic agents impose on com-
plement susceptibility when cells are challenged with
antibody-directed complement activation could provide
Percent Lysis following Glutamine Synchronization and Neu- tralization of CD59 Figure 7
Percent Lysis following Glutamine Synchronization and Neu-
tralization of CD59. Treatment groups were prepared as 
outlined for unsynchronized, glutamine deprived and 
glutamine restored populations of Bcap37 and MCF7 cells. 
Cells were sensitized with 20 µg of rabbit polyclonal anti-
body to β2-microglobulin and subjected to 25% fresh normal 
human serum (NHS) in combination with 20 µg of YTH53.1 
rat monoclonal antibody to CD59. After 4 hours of incuba-
tion with NHS at 37°C, supernatants were collected and 
tested for LDH activity to determine percent lysis. Please 
note the increase in percent lysis for both cell lines as com-
pared to Figure 6.Cell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
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valuable information in designing more effective immu-
notherapeutic treatments. From our studies, a theoretical
advantage may be obtained from combining medical
agents which increase complement susceptibility of can-
cer cells, either through reduced mCRP expression or
altered metabolic profiles, with complement activating
antibody-directed immunotherapeutic treatments.
In terms of the immunological privilege often associated
with neoplasms, low levels of sustained, albeit ineffective
complement deposition (e.g., at the tumor site) have been
shown to propagate cancer cells that are more resistant to
apoptotic signals [19] and concomitantly the surviving
cells become even more resistant to complement-medi-
ated damage [17,18]. This could partially explain why
limited non-lethal in vivo complement activation local-
ized to the tumor site could exacerbate the inherent
pathology associated with malignancy, therein-complicat-
ing treatment efforts [18]. Malignant cancer cells also lib-
erate soluble forms of complement mCRPs that maintain
their complement-restrictive activities [4]. Thus, the eva-
sive properties of malignant cancer cells may be attributed
to an interrelated, yet not fully understood, complex of
resistance mechanisms that promote cell survival and
immunological privilege. Future studies will hopefully
delineate the impact of specific molecular pathways asso-
ciated with non-lethal complement activation and
glutamine deprivation or chemotherapy on the immuno-
logical privilege and chemotherapeutic resistance com-
monly identified in malignant breast cancer cells.
Conclusion
Glutamine deprivation resulted in increased complement
susceptibility and altered cell cycle profiles in breast can-
cer cells. However, glutamine restoration led to a rapid
progression through the mitotic cell cycle, as well as
increased CD59 and CD55 expression, which correlated
with increased resistance to antibody-directed comple-
ment activation. When CD59 is neutralized, both
glutamine-deprived and glutamine-restored breast cancer
cells demonstrated increased complement susceptibility.
These findings are important when considering the design
of antibody-directed immunotherapies which attempt to
selectively target cancer cells for complement-mediated
killing.
Methods
Cell culture media and glutamine synchronization
The human breast adenocarcinoma cell line MCF7 [23]
and the human breast medullary carcinoma cell line
Bcap37 [24] were obtained from the Hollings Cancer
Center at the Medical University of South Carolina. The
MCF7 cells have been extensively examined for expression
of  β2-microglobulin [23]. Adenocarcinomas are much
more common than medullary mammary carcinomas,
however these two very distinct cell types were employed
for comparative purposes. Cell lines were customarily
maintained in Delbecco's Modified Eagle Medium
(DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 2 mM L-glutamine, 50 units/ml of
penicillin and 50 µg/ml of streptomycin at 37°C in
humidified air with 5% carbon dioxide. All media and
supplements were obtained from Fischer Scientific.
Cells were grown to confluence and then to establish
treatment groups, approximately 1 × 105 MCF7 or Bcap37
cells were inoculated onto 48-well plates. For 24 hours,
treatment groups were allowed to adhere to the plate sur-
face in DMEM media supplemented with 10% FBS, anti-
biotics and 1 mM L-glutamine at 37°C. Next, the media
was removed and cells were washed with sterile PBS. As is
well-known, L-glutamine is an essential component for
cell growth (Minamoto, et al, Cytotechnology. 1991;5
Suppl 2:S35-51). Treatment groups were then established
based on glutamine supplementation and identified as
unsynchronized, glutamine deprived or glutamine
restored. "Unsynchronized" cells continued to grow unin-
terrupted for 48 hours in standard DMEM culture media
with additional supplements as detailed above. The
"glutamine deprivation" group received DMEM with 5%
FBS, antibiotics, but no glutamine for 48 hours. The con-
version from 10% FBS to 5% FBS minimized untoward
exposure of cells to extraneous L-glutamine occasionally
contained in FBS preparations, but contains an adequate
amount of the essential serum elements required to sup-
port basic cellular activities for 48 hours [39]. Addition-
ally, we have observed Bcap37 and MCF7 cell lines can be
continuously grown in DMEM supplemented with 5%
FBS and 2 mM L-glutamine. The "glutamine restored"
cells were treated identical to the "glutamine deprived"
cells for 48 hours, but then received DMEM with 10% FBS
and 2 mM L-glutamine for 8 hours before harvesting. The
48-hour period of glutamine-deprivation synchronized
cells in a quiescent G0-G1 phase of the cell cycle, allowing
comparison of glutamine-deprived cells with unsynchro-
nized cells and cells treated with glutamine deprivation
followed by glutamine restoration.
Complement-activating antibodies and normal human 
serum
Approximately 1 × 105 MCF7 or Bcap37 cells were inocu-
lated onto 48-well plates with each well supplemented
with DMEM media with 10% fetal bovine serum (FBS),
antibiotics, and glutamine. To induce complement activa-
tion, cells were sensitized with either 10 µg (20 µg/ml) or
20 µg (40 µg/ml) of rabbit polyclonal antibody to human
β2-microglobulin (anti-β 2M, Accurate Inc.), a ubiqui-
tously expressed cell surface marker associated with Major
Histocompatibility Complex-1 antigen [25]. When indi-
cated, antibody-mediated neutralization of CD59 func-Cell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
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tion was achieved using YTH53.1 (Serotec), a rat
monoclonal antibody to CD59 proven to neutralize its
complement-inhibitory function (37,38). The YTH53.1
has demonstrated high specificity for human CD59 and
effectively neutralizes it complement inhibition proper-
ties, thus negative antibody controls testing the specificity
of YTH53.1 were not necessary (37,38, 42, 43). Specified
amounts of 0, 5, 10, or 20 µg representing 0 µg/ml, 10 µg/
ml, 20 µg/ml and 40 µg/ml absolute concentrations of
YTH53.1 were added in combination with an optimized
level (20 µg) of rabbit polyclonal anti-human β2-
microglobulin (anti-β 2M). Following antibody treat-
ments, cells were incubated with normal human serum as
a source of complement. Normal human serum (NHS)
was obtained from venous blood donated with consent
by healthy volunteers (blood was allowed to clot for one
hour at room temperature and for two hours on ice-water,
then centrifuged, aliquoted and stored at minus 80°C).
Specified dilutions of NHS were made in sterile isotonic
barbital buffered saline, BBS++ (0.15 mM Ca++ and 1.0 mM
Mg++), pH 7.3 and placed in frozen storage. Aliquots were
thawed in warm water bath for 30 minutes prior to use.
Lactate dehydrogenase-release-assay to detect 
complement-mediated damage
Lactate dehydrogenase (LDH) is an intracellular enzyme
released into the extracellular environment when a cell is
damaged by lytic perforations induced in the cell mem-
brane via complement activation. Triplicate LDH assays
were performed with 48-well plates (Fischer Scientific)
with each sample containing approximately 1 × 105 MCF7
or Bcap37 cells. Incubations with NHS were for 30 min at
37°C; then 0.4 mM PMSF was added to prevent degrada-
tion of LDH by endogenously released intracellular pro-
teases. Subsequently, these cells were incubated with the
human serum for 4 additional hours at 37°C to elicit a
maximum cellular response to complement activation.
Application of PMSF simultaneously blocks new comple-
ment activation, yet we have observed that with addi-
tional time the cells with damaged membranes expand
[26] and release LDH. Background detection of LDH was
obtained with 1 × 105 cells incubated without antibodies
in the presence of NHS, and was subtracted from experi-
mental values. The LDH-assay solution (Sigma Diagnos-
tics) was prepared according to the standard commercial
protocol provided by Sigma Diagnostics. After each treat-
ment group was incubated with NHS and specified anti-
body combinations, 50 µl samples were taken from the
supernatant and added to 1 ml of the LDH-assay solution,
mixed thoroughly and read at 340 nm. Total (100%) lysis
was obtained by treating the cells with 1% Triton-X100
detergent. The percentage of lysis was determined by
dividing the experimental LDH activity by the total lysis
LDH value. At the conclusion of each LDH assay, Trypan
Blue exclusion was used to corroborate the percentage of
cells with membrane damage (percent of living cells) as
compared to the LDH assay. An ANOVA statistical analy-
sis revealed no significant variation between the commer-
cial LDH detection assay and the Trypan Blue exclusion,
revealing the LDH detection method to be a reliable
method in the determination of complement-mediated
cell membrane damage. In addition, Trypan Blue exclu-
sion was used to verify viability of all cells at harvesting
following control and experimental treatments.
Flow cytometry: determination of cell cycle distribution 
and mCRP expression
Unsynchronized or glutamine synchronized treatment
groups were prepared for flow cytometry analysis. Cells
were harvested with cold Versene (Gibco) to obtain a sin-
gle-suspension of cells and then centrifuged at 1000 rpm
for 5 min at 27°C. Pellets were re-suspended in 1%
bovine serum albumin (BSA) blocking solution and cen-
trifuged at 1000 rpm (200 g) for 5 min at 27°C. Pellets
were re-suspended in serum-free DMEM and aliquots of
approximately 1 × 106  cells were probed with FITC-
labeled monoclonal antibody to either CD55 (2 µg/ml
mouse IgG1 BRIC-216, Serotec Inc.) or to CD59 (2 µg/ml
mouse IgG2a, MEM43, Serotec Inc.). Isotype (negative)
controls were non-specific FITC-labeled mouse immu-
noglobulins, IgG2a and IgG1. Concomitantly, cells were
fixed with ice-cold 95% ethanol (pH 7.4). The cells were
resuspended in 100 µl of 0.5 mg/ml propidium iodide
and 0.1 mg/ml ribonuclease A in 0.15 M PBS. The treated
cells were filtered through a 35-µm cell-strainer and ana-
lyzed using a FACSCalibur™ (Becton Dickinson) flow
cytometer with a 488 nm argon-ion laser for excitation.
Light emission as a function of propidium iodide interca-
lated within DNA (to identify the cell-cycle) was detected
using a 585 nm bandpass filter and the data analyzed
using ModFit LT™ (Verity) software. Populations of cells
were identified in either G0-G1 or G2-M based on chan-
nel values dictated by the amount of propidium iodide
present in each cell, representing different stages of cell
cycle. All Diploid cells were identified, then separated
according to channel values based on propidium iodide
fluorescence at 585 nm. Cells identified as G0-G1 had
channel values ranging approximately from 25 to 75.
Cells identified as G2-M had channel values ranging
approximately from 140 to 175. Gating was performed
manually after identification of G0-1 and G2-M popula-
tions to further determine CD59 and CD55 Mean Fluores-
cent Intensity (MFI) among these distinct populations of
cells at different stages in the cell cycle. The acquisition
threshold was set at 5,000 cells using the ModFit LT soft-
ware, which allowed 5,000 diploid cells to be identified in
the G0-G1 and G2-M channel ranges, and then these cells
were further evaluated for MFI of CD59 and CD55 expres-
sion. Using the negative background isotype controls
(non-specific FITC-labeled mouse immunoglobulins, IgG2aCell Division 2007, 2:20 http://www.celldiv.com/content/2/1/20
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and IgG), no binding of the negative control antibodies to
the cell surface was identified among MCF7 and Bcap37
cells. The positive fluorescent antibody control (fluores-
cently tagged anti-β2-microglobulin) revealed uniform and
near-ubiquitous expression of β2-microglobulin among
all MCF7 and Bcap37 cells irrespective of cell cycle phase
or glutamine synchronization. Data was analyzed using
CellQuest™ (Becton Dickinson) software. Instrument per-
formance was routinely monitored using DNA QC Parti-
cles and Calibrite™ beads (Becton Dickinson).
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